Pharmaceutical salt of BM635 with improved bioavailability

[1]  A. Nangia,et al.  Enhanced Bioavailability in the Oxalate Salt of the Anti-Tuberculosis Drug Ethionamide , 2016 .

[2]  A. P. Voronin,et al.  Pharmaceutical salts of ciprofloxacin with dicarboxylic acids. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  E. Kwong,et al.  Advancing drug discovery: a pharmaceutics perspective. , 2015, Journal of pharmaceutical sciences.

[4]  G. Desiraju,et al.  Salt and cocrystals of sildenafil with dicarboxylic acids: solubility and pharmacokinetic advantage of the glutarate salt. , 2013, Molecular pharmaceutics.

[5]  Robert H Bates,et al.  Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection , 2013, PloS one.

[6]  Hywel D Williams,et al.  Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.

[7]  S. Onoue,et al.  Development of Meloxicam Salts with Improved Dissolution and Pharmacokinetic Behaviors in Rats with Impaired Gastric Motility , 2012, Pharmaceutical Research.

[8]  Li Di,et al.  Bridging solubility between drug discovery and development. , 2012, Drug discovery today.

[9]  J. Sacchettini,et al.  MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212 , 2011, Antimicrobial Agents and Chemotherapy.

[10]  Patrick Sandra,et al.  The utility of sulfonate salts in drug development. , 2010, Journal of pharmaceutical sciences.

[11]  M. Peterson,et al.  Salt Screening and Selection , 2010, Burger's Medicinal Chemistry and Drug Discovery.

[12]  C. Rudin,et al.  A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies , 2010, Cancer Chemotherapy and Pharmacology.

[13]  Patrick Sandra,et al.  Mechanism and Processing Parameters Affecting the Formation of Methyl Methanesulfonate from Methanol and Methanesulfonic Acid: An Illustrative Example for Sulfonate Ester Impurity Formation , 2009 .

[14]  Ron J Roberts,et al.  Structure, solubility, screening, and synthesis of molecular salts. , 2007, Journal of pharmaceutical sciences.

[15]  R. B. Walker,et al.  Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  Hassan Almoazen,et al.  Investigation of Solubility and Dissolution of a Free Base and Two Different Salt Forms as a Function of pH , 2005, Pharmaceutical Research.

[17]  B. Bain,et al.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.

[18]  O. Corrigan,et al.  Preparation and characterisation of a range of diclofenac salts. , 2001, International journal of pharmaceutics.

[19]  D. Elder.  Physicochemical and crystallographic investigations into the salt formation of two heterocyclic drugs , 1992 .